Belgian Pharma Co to Pay $34M for Off-Label Drug Promotion
The Justice Department has announced that the U.S. subsidiary of Belgian pharmaceutical manufacturer UCB SA has pleaded guilty to the off-label promotion of its epilepsy drug Keppra for use in the treatment of migraines, in violation of the Food, Drug…
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
and Cosmetic (FD&C) Act. UCB will pay more than $34 million to resolve criminal and civil liability arising out of its illegal conduct.